LMAT Raises Q2 Guidance, Outpacing Wall Street Expectations

Forward-Looking Analysis

Wall Street consensus anticipates Lemaitre Vascular (LMAT) to report Q2 2026 earnings per share (EPS) of $0.70, with estimates ranging from $0.69 to $0.70. Analysts project quarterly revenue at $71.5 million. Company management has issued specific guidance for the quarter, forecasting EPS between $0.79 and $0.84 and revenue between $70.5 million and $72.5 million. This guidance significantly exceeds the initial consensus EPS estimate of $0.75 and revenue estimate of $71.1 million, indicating strong management confidence. For the full fiscal year 2026, LMAT has raised its GAAP EPS guidance to a range of $2.93–$3.08, up from the previous $2.81–$3.01, while maintaining revenue guidance between $277.0 million and $283.0 million. Analyst forecasts for the next three years suggest steady growth, with average EPS estimates rising from $3.06 in 2026 to $3.58 by 2028. Revenue is similarly projected to grow from $285.6 million in 2026 to $339.5 million by 2028. Despite this growth, LMAT’s forecast earnings growth rate of 9.07% lags behind the US Medical Instruments & Supplies industry average of 27.82% and the broader market’s 34.46%. However, its revenue growth forecast of 9.76% slightly outperforms the industry average of 9.35%. Return on equity is forecast at 21.27%, considered strong, though return on assets at 13.74% trails the industry average of 18.2%. Wall Street analysts maintain a "Buy" consensus, with four analysts covering the stock: one Strong Buy, two Buys, and one Hold. The average 12-month price target is $117.00, representing a 14.26% upside from the current price of $102.40, with a high target of $127.00 and a low of $104.00.

Historical Performance Review

Lemaitre Vascular delivered a robust performance in Q1 2026, exceeding analyst expectations. The company reported revenue of $66.55 million, a slight miss against the $66.67 million consensus but reflecting an 11.1% year-over-year increase. Earnings per share came in at $0.69, beating the $0.66 estimate by $0.02. Net income reached $15.68 million, supported by a gross profit of $48.40 million. This beat continues a recent trend of positive surprises, having also beaten Q4 2025 and Q3 2025 estimates. The trailing EPS stands at $2.71, and the stock currently trades at a P/E ratio of 37.96.

Additional News

Management remains active in investor relations to highlight growth prospects. On May 20, 2026, LeMaitre announced participation in the Jefferies Global Healthcare Conference on June 3, 2026, in New York City. Prior to this, on May 7, 2026, the company confirmed a presentation at the Bank of America Healthcare Conference on May 13, 2026. These engagements follow the Q1 2026 earnings release on May 5, 2026, where the company announced a quarterly dividend of $0.25 per share and provided updated financial guidance. Historically, LeMaitre has issued 31 guidance updates between October 2022 and May 2026, raising its outlook 17 times and lowering it 13 times, demonstrating active management of investor expectations. The company continues to focus on its core business of vascular devices, implants, and cryopreservation services, with recent growth driven by products like the Artegraft biologic graft and strong international performance in EMEA and APAC regions.

Summary & Outlook

Lemaitre Vascular exhibits solid financial health, characterized by consistent revenue growth and expanding margins. The company’s Q2 guidance suggests a significant upside potential, as management forecasts EPS of $0.79–$0.84, well above the $0.70 consensus. Key growth catalysts include strong organic sales growth, international expansion, and product launches like Artegraft. However, risks include slower earnings growth relative to the broader market and industry peers. Given the raised guidance and consistent beat history, the outlook is cautiously bullish. Investors should monitor the Q2 results for confirmation of the upward guidance trajectory and sustained momentum in international markets.